GlassScriptPhysician profile
Inna Yaskin
NPI 1316965353
$10,436.66
in general payments reported to CMS, 2019-2025
52 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,007 · 2020: $2,967 · 2021: $3,491 · 2022: $1,372 · 2023: $159 · 2024: $340 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,136.50 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $1,219.93 | 2021 | |
| Novo Nordisk INC | $745.12 | 2019-2024 | Wegovy |
| Allergan, INC. | $458.64 | 2019-2020 | |
| Amgen INC. | $446.26 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $413.99 | 2019-2022 | |
| Lilly USA, LLC | $395.86 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $333.08 | 2019-2022 | |
| Abbvie INC. | $271.34 | 2022-2023 | Qulipta |
| Merck Sharp & Dohme LLC | $255.32 | 2019-2023 | Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $249.58 | 2022 | |
| Amarin Pharma, INC. | $222.16 | 2020 | |
| Pfizer INC. | $178.26 | 2019-2020 | |
| Medtronic, INC. | $171.42 | 2024 | Azure Xt Dr Mri Surescan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.71 | 2019-2020 |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Yaskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.